Annovis Bio Inc (ANVS)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$0.67-44.72%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ANVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
ANVS — legal / regulatory event — Notice of Delisting or Failure to
Dated 2026-10-30
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 29, 2026, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $5…
Why it matters: Annovis has 45 days to file a plan and nine months to regain compliance. Rejection can start delisting steps.
Worry ifThe NYSE rejects the plan, or Annovis misses the 45-day filing deadline.
Less concerning ifThe NYSE accepts the plan, and Annovis stays listed while it works to meet the rules.
Why it matters: The Phase 3 trial tests buntanetap’s effect on thinking and daily function. The results are a key test of the drug.
Watch forQ1 2027 data show both main measures, ADAS-Cog13 and ADCS-iADL, met their targets.
Also watch forQ1 2027 data show one main measure missed its target, or the results are delayed.
Why it matters: The extension lets trial patients keep taking buntanetap after the main study. A start would match the company’s stated plan.
Supportive ifAnnovis says the AD extension began in October 2026.
Worry ifAnnovis reports that the extension has not started, or gives a later start date.
Why it matters: Annovis reported $18.7 million in cash and a $14.4 million quarterly operating loss. New figures can show how its cash position changed.
Worry ifThe November 11 results show cash below $18.7 million. No financing proceeds were disclosed to make up for the drop.
Less concerning ifThe results report cash at or above $18.7 million, or name financing proceeds that offset the cash decline.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$290 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $818 loss on $10,000 · 8.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,688 loss on $10,000 · 86.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.